INOVIO, a biotechnology company focused on precisely designed DNA medicines to treat and prevent infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou, an emerging biotech company with next-gen technology in vaccines, have entered into a collaboration and license agreement for COVID-19 DNA vaccine candidate INO-4800.   Advaccine will have the exclusive right to develop, manufacture and commercialize INO-4800 in Greater China. Advaccine will license its plasmid manufacturing p...